371 related articles for article (PubMed ID: 25875396)
1. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
[TBL] [Abstract][Full Text] [Related]
2. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
[TBL] [Abstract][Full Text] [Related]
3. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
[TBL] [Abstract][Full Text] [Related]
4. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
5. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
[TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
[TBL] [Abstract][Full Text] [Related]
7. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
[TBL] [Abstract][Full Text] [Related]
8. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
[TBL] [Abstract][Full Text] [Related]
11. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
[TBL] [Abstract][Full Text] [Related]
12. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
14. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
[TBL] [Abstract][Full Text] [Related]
15. A validated method for simultaneous quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients.
Ludna Duarte M; Mikaelle Brandão Silva A; Wellithom Viturino da Silva J; Pereira Santana D; Victor de Castro W; Cláudio Arraes de Alencar L; César Galindo Bedor D; Bastos Leal L
Clin Biochem; 2024 May; 127-128():110765. PubMed ID: 38649089
[TBL] [Abstract][Full Text] [Related]
16. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R; Roberts J; Martin-Carpenter L; Zala C
Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
[TBL] [Abstract][Full Text] [Related]
18. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
[TBL] [Abstract][Full Text] [Related]
20. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
